Table 3.

Real-world effectiveness of treatment as assessed by the treating physician (n = 41/42*)

Variable	Response, % (n/N) [95% CI]
Overall	70.7 (29/41) [54.5 to 83.9]
Probable aspergillosis	71.8 (28/39) [55.1 to 85.0]
Proven aspergillosis	50.0 (1/2) [37.4 to 74.5]
Combination therapy**	80.0 (4/5) [28.4 to 99.5]
Monotherapy	69.4 (25/36) [51.9 to 83.7]
First-line therapy***	63.6 (7/11) [30.8 to 89.1]
Second-line therapy	73.3 (20/30) [54.1 to 87.7]
Neutropenic status at start of caspofungin therapy
Neutrophilic granulocytes < 500/uL	71.4 (20/28) [51.3 to 86.8]
Neutrophilic granulocytes ≥ 500/uL	69.2 (9/13) [38.6 to 90.9]
Risk factors****
Allogeneic HSCT	87.5 (7/8) [47.3 to 99.7]
Acute renal disease	80.0 (4/5) [28.4 to 99.5]
Neutropenia at hospitalization	70.4 (19/27) [49.8 to 86.2]
Active cancer	69.2 (27/39) [52.4 to 83.0]
Immunosuppressive therapy	68.4 (26/38) [51.3 to 82.5]
Prior colonization with fungi	66.7 (4/6) [22.3 to 95.7]
Autologous HSCT	50.0 (2/4) [6.8 to 93.2]

* No data were available for one lung transplant patient with proven aspergillosis (A. fumigatus), who had received triple combination therapy (amphotericin B, caspofungin, voriconazole). If this patient is regarded as a failure, the response rate for all 42 patients is: favorable response, 29/42 patients (69%; 95% CI 53 to 82%).

** Combination of caspofungin with amphotericin B desoxycholate (two patients), with fluconazole (one patient), with posaconazole (one patient), with amphotericin B desoxycholate plus voriconazole (one patient). Note, if the patient described in * is included in the effectiveness population and (post hoc) counted as a failure, the response rate for patients with combination therapy is 66.7% (4/6) and the 95% confidence interval is 22.2% to 95.7%.

*** All patients receiving caspofungin first line were on monotherapy.

**** Multiple answers possible.